Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide.

To assess reduction in prostate-specific antigen (PSA) levels among Black and non-Black patients treated with apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic castration-sensitive prostate cancer (mCSPC). Patients were identified from electronic medical data. PSA reduction (≥50%, ≥90% or below 0.